atic relief of symptoms, and three had no clinical change (3) . Wi th th is, WagnerJauregg essentially opened the door for the biological therapy o f mental illness.
The 1930's were an exciting time in the treatment of schizoph ren ia. Three therapies,-all extrapolations of Wagner-Jauregg's th eory-were devel oped within a several year period. These included: insulin induced hypo glyce mia , pharmacologically induced convulsive therapy, and leukotom y. T he first of these was Manfred Sakel's insulin induced hypoglycemia. Although the h ypo glycemia induced by Sakel occasionally resulted in convulsion, he did not beli eve that the convulsion was therapeutically necessary. Rather, Sakel felt that the hypoglycemia restricted the activity of that portion of the central nervous syste m which was responsible for the psychopathology (4).
Sakel's technique was followed in 1934 by Ladislas Meduna's pharmaco logically induced convulsive therapy, which will be discussed later. Then, in 19 36 , Egas Moniz developed the technique of leukotomy (lobotom y) for the tr eat m ent of psychosis. Moniz was later awarded a Nobel Prize in 1949 for hi s work o n the psychosurgerical treatment on schizophrenia.
Ladislas Meduna, who graduated from the University of Budapest Sch oo l o f Medicine in 1921, attempted to treat schizophrenia by inducing seizu res in his patients. This theory was based on what Meduna felt to be a " b iologic antagonism between the epileptic state and schizophrenia (5) . " Specificall y, he observed clinically that patients with schizophrenia frequentl y had a decrease in their psychotic symptoms after spontaneous seizures. Moreover, based on autopsy findings, Meduna reported that epileptic brains were associated with a "hyperplasia" of the glial system while schizophrenic brains were associ ated wit h a "torpor" of this system (3). He therefore proposed that pharmacologicallyinduced seizures may be of benefit for the treatment of schizophrenia.
However, Meduna commented in his unpublished auto-biography:
.. . at this time, however, I did not dare to think of cu r ing schizoph renia, partly because ... to us, schizophrenia was an endogenous, hereditary disease. Both expressions, endogenous and hereditary, meant that the fate of the patient was determined at th e moment of conception; the disease anchored in the ovum and spe r m; no thing could change that fate (6) .
Despite his reservations, Meduna eventually decided to test his th eo r y. On January 23, 1934, he gave an intramuscular injection of camphor o il to a pa tient who had been in a catatonic stupor for four years. Meduna d escribed the dramatic im p roveme n t in this patient with five camphor oi l ind uced seizures:
... on the morning of February 10, 1934, (two days aft er the fifth injection) for the first time in four years, he got out of bed, began to talk, requested breakfast, dressed himself without any help, was interested in everything around him, and asked how long he had bee n in the hospital. When we told him that he had spent four yea rs, he d id not believe it (6).
After severa l trials with camphor oil , Meduna switc hed to pentylenetrazol (Metrazol) as the epileptogenic stimulant because it produced an immediate convulsion . Despite the initial criticism and oppositi on, pharmacologicallyinduced seizures remained a preferred treatment modali ty for schizophrenia until the advent ofECT.
In 1935, Meduna published " Vers uche Uber Die Biolo gisch e Bee influssu ng Des Ablaufes Der Schizophrenie" ("Attempts To Influence T he Cause of Schizophrenia By Biological Means") which documented the results of his first twenty-six schizophrenic patients to have pharmacologi call y ind uced seizures (7) . The results suggested that there did indeed seem to be an antagonistic relationship between schizophrenia and convulsive episodes. Ten of the twentysix patients reportedly improved while sixteen were without clinical improvement. Of note, the patients who did improve had recei ved, o n the average, 6.2 seizures; on the other hand, those who did not improve had an average of only two seizures per patient. De spite these results, Meduna 's work was met with much criticism . Meduna, in his autobiography, recall ed th e reaction of Dr. Karl Schaffer, the department chairman at the University of Budapest:
. .. he (Schaffer) called me a swindler, a humbug, a cheat ... how dare I claim that I cured schizophrenia, an endogenous, heredi tar y disease. He knew what was in my mind-to publish , get newspaper publicity, and make money! "If you dare publish this paper I d isown you. " ... this incident was the first shock I rec eiv ed for the disc overy of shock therapy (6).
Ugo Cerletti, the chair of the Department of Neuropsych iat r y at the University of Rome, utilized Meduna's pharmaco-convulsive therapy for the treatment of hi s schizophrenic patients. Cerletti, wh ose laborator y research involved an examination of the histopathologic changes in A m mon's horn of dogs brains following electrically ind uced seizu res, postulated that electricity could be substituted for Metrazol as the convulsive st imu lus for the treatment of psychosis. However, Cerletti was reluctant to pursue this theory:
.. . the idea of submitting a man to co nv u lsant el ectric di sch arges was considered as utopian, barbaric, and dangerous; in everyone's mind was the specter of the electric chair (6).
Cerletti's ac ademic peers attempted to di ssu ade him from e lectrically inducing conv u lsio ns in man. Among the arguments used against his p roposal was the idea that transcranial electricity was used to kill pigs in slaughter houses in Rome. H owever, Cerletti determined, in research he perfo r med at local slaughter houses, that the pi gs were ac tually put into an elec trically-in d uced epileptic co ma during wh ich tim e th eir necks were slashed. Ce rletti foun d that pigs could ac tua lly tol erate a significant vo ltage ac r oss th e head wit hout subsequent death.
Lu cino Bini , who had no fo r m al tra ining in psyc hiatry, worked with Cerletti o n th e tech nical aspects of e lec tr ica l co nv u lsio ns . Bini noted that there was a high mortality in Cerletti's laboratory dogs following induced seizures. He determined that this was secondary to the Viale method of e lectrode p lacement in which the electrodes were placed in the dogs mouth and rectum . This permitted electrical current to travel through the heart and occasionally cause fatal arrh ythmias. Bini subsequently initiated exper iments with bitemporal electrode placement.
After significant deliberation and animal experimentation , Ce rlett i and Bini were prepared to attempt ECT in man . In April , 1938 t he first ECT was performed by Cerletti and several members of his staff-Bini , Langhi , Acconero, and Kalinowsky. Cerletti described the first patient, a 40 year old schizophrenic:
... He expressed himself exclusively in an incomprehensibl e gib berish made up of odd neologisms and, since his arri val from Milan b y train without a ticket, not a thing had been ascertainable about his identity (8).
Dr. Cerletti described the first ECT as follows:
... as was our custom with dogs, Bini and 1 fixed th e two electrodes well wetted in salt solution, b y an elastic band to th e patien t 's te mples. As a precaution, for our first test, we used reduced tensio n (70 vo lts) with a duration of 0.2 seconds. Upon closing the circ uit, th ere was a sudden jump of the patient on his bed with a very sho r t tensing of a ll his muscles; then he immediately collapsed on to th e bed without loss of consciousness.
The patient presently started to sing at the top of his vo ice, then fell silent. It was evident from our experience with d ogs th at the voltage had been held too low (8) .
At this point, there was controversy among the observers wh ether a re peat stimulus at a higher voltage should be attempted. In the midst o f th is disc ussion, the patient pleaded, in language that was no longer incomprehensibl e , "non una seronda! mortifera!" ("not again it will kill me!"). Cerletti decided , against the majority opinion , to repeat the electric stimulus: 1 (Cerletti) had the electrodes reapplied, and a 110 volt di sch arge was sent through for 0.5 seconds. The immediate, very brief cra mping of all the muscles was once again seen; after a slight pause , th e most typical epileptic fit began to take place. True it is that all had their hearts in the mouths and were truly oppressed during th e to nic p hase with apnea, ashy paleness, and cadaverous faci al cya nos is-an ap nea which, if it be awe inspiring in a spo n taneo us epileptic fit , no w seemed painfully never ending-until at the first deep, ster to rous in halat io n, and first chronic shutters, the blood ran more freel y in th e bystanders veins as well: and, lastl y, to the immense relief of all co ncerned, was witnessed a characteristic, gradual awakening by step . The pati ent sat up of his own accord, looked about him calmly with a vague sm ile, as though asking what was expected of him. I asked him "what has been happening to you?" He answered, with no more gibberish: " I d on 't know, perhaps I have been asleep (8) ."
The initial patient received thirteen more treatments of ECT over a two month period and was discharged in complete remission. Unfortunatel y, the patient was lost to follow-up after two years; but, he remained symptom free until that time. The first public presentation of ECT was giv en b y Cerletti at the Medical Academy of Rome in May, 1938. ECT gradually gained acce p ta nce for the treatment of schizophrenia across Europe and by 1943 it had crossed t he Atlantic and was being used in America.
Although ECT, at its inception, was used primarily for th e treatm en t of schizophrenia, investigators explored the efficacy of this treatment modal ity for the entire gamut of psychiatric disorders. Within several years , ECT was a relatively common treatment for the affective disorders, esp eciall y d epression with psychotic features and severe mania. Approximately 15 year s afte r the first trial of ECT,jarrie estimated, in a paper on the treatment of affecti ve di sord er s, that one third of the 60,000 hospitalized patients in England and Whales wo uld receive ECT (9) .
The use of ECT was not without potential side-effects and co mplications. Among these problems were a risk of fractures (especially of th e ex tre m ities and spinal compression fractures), a relatively high degree of psychic di str ess experienced b y the patients, and cognitive changes following treatments. Several advances were made over the subsequent years to alleviate th ese p robl ems. Bennet, a ps ychiatrist, was instrumental in determining the muscle-relaxing agent used by South American hunters to paralyze their prey. H e was abl e to use this agent, curare, during ECT and therefore significantly decreased th e ris k of fractures (10) . Succinyl-choline was later substituted for curare becau se of its improved side-effect profile (II). In addition to muscle relax ants, barb itu rates were administered both to decrease the patient's subjecti ve anxiety prior to treatment and to decrease the anxiety associated with paralysis. With respect to th e cognitive changes, it was determined that the un ilat eral , as opposed to bitemporal, administration of the electrical current wou ld sti ll res u lt in a generalized seizure and was less likely to produce cognitive changes. T hese advances significantly decreased the complications and side-effec ts associated with ECT.
The use of ECT in the 1940's was flourishing as there was no other effecti ve treatment for psychiatric disorders. However, with the introducti on of neuroleptic medication, and subsequently antidepressants, ECT was used with decreasing frequency. The administration of psychotropic medication was less tim e consuming and certainly did not have the stigma associa ted with it th at ECT d id . In addition, much of the funding for research on the treatme nt of psychiatric disorders was provided by pharmaceutical companies.
The psychotropic medications were not, however, the panacea that man y people had hoped. They did not have 100% cure rate and we re also associated with occasional side-effects and complications. Thus, despite th e d ecline in ECT use following the introduction of psychotropic medication, th e 1980's saw a gradual resurgence of ECT. In the United States in 1980, 2.5 % of all hospi ta lized psychiatric patients received ECT; and 13 % of all patients ad mitted to a hospital with a primary diagnosis of an affective disorder received ECT ( 10) . While it is difficult, if not impossible, to perform a statistically sound study of the efficacy ofECT, it has been suggested that ECT is at least as effective, if not more effective, in the treatment of depression than psychopharmacologic interventions.
Despite the resurgence of ECT, this continues to be a n ext remely controversial treatment for psychiatric disorders. The negative asp ect of ECT is adva nced by movies like One.flew Over The Cuckoo's Nest and the anti-psychiatry mo vem e nt. Sources like these often advance the view that ECT is a psychi atri c tool of punishment and retribution.
In conclusion , the use of electricity for therapeutic purposes da tes to ancient medicine. However, the concept of using electricity as a co n vu lsive agent fo r the treatment of psychiatric disorders can be directly traced to th e pha rmacoconvulsive therapies of Meduna. Over the yea r s, significant improveme nts h a ve been made in the administration of this treatment in order to sign ificantl y decrease the associated adverse effects. At the present time, EC T appears to be as effective as pharmacologic interventions for th e treatment of psych iat r ic disorders. But, for many reasons, including the social stigma associated with its use, ECT is most frequentl y used only as a last line of therapeutic in terve ntio n.
